SLAMF6 and cancer: In conclusion, we describe a completely novel immune escape mechanism in cancer, in which AML cells induce aberrant expression of the lymphocyte marker SLAMF6 and thereby inhibit T cell-mediated killing, in a process analogous to the PDL1–PD1 interaction.